))
Episode 32: t(11;14) Multiple Myeloma and Role of Venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser
Manage episode 380166964 series 3369804
Innhold levert av Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In this episode, we discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax with Dr. Rafael Fonseca and Dr. Martin Kaiser.
Here are the shownotes:
1. Excellent tweetorial thread by Dr. Fonseca highlighting some of the historical studies that identified t(11;14) and its prognostic impact in myeloma:
https://x.com/Rfonsi1/status/1206004966294294528?s=20
2. Natural history of t(11;14) myeloma in the era of PIs and IMiDs:
https://pubmed.ncbi.nlm.nih.gov/28655925/
3. BELLINI trial (Ven-Bort-Dex vs Bort-Dex in all-comers):
https://pubmed.ncbi.nlm.nih.gov/33129376/
4. Efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis:
https://pubmed.ncbi.nlm.nih.gov/36779691/
5. CANOVA Trial (Ven-Dex vs Pom-Dex in t[11;14]):
https://www.clinical-lymphoma-myeloma-leukemia.com/issue/S2152-2650(23)X0011-1?pageStart=0
6. Phase 1/2 trial on Daratumumab-Venetoclax-Dex in Relapsed/Refractory Myeloma:
https://pubmed.ncbi.nlm.nih.gov/34388020/
7. Phase 1/2 trial on Venetoclax-Carfilzomib-Dex in relapsed/refractory myeloma:
47 episoder
Del
